SCHEMBL3354878

SCHEMBL3354878

C[C@H](NC(O)CCNC(=O)O)c1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASR P41180 3/20 0.54
MTNR1A P48039 1/20 0.49
MTNR1B P49286 1/20 0.49
CNR1 P21554 2/20 0.44
CNR2 P34972 2/20 0.44
POLB P06746 1/20 0.44
CTDSP1 Q9GZU7 1/20 0.44
EPHX2 P34913 3/20 0.44
APAF1 O14727 1/20 0.44
CHRM2 P08172 1/20 0.44
HTR1A P08908 1/20 0.44
ADRA2A P08913 1/20 0.44
ADORA3 P0DMS8 1/20 0.44
CHRM1 P11229 1/20 0.44
SMPD1 P17405 1/20 0.44
DRD1 P21728 1/20 0.44
TBXA2R P21731 1/20 0.44
SLC6A2 P23975 1/20 0.44
SLC6A4 P31645 1/20 0.44
ADRA1A P35348 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3357319 1.00 CASR (0.54) CASRMTNR1AMTNR1BCNR1CNR2
SCHEMBL3357685 1.00 CASR (0.54) CASRMTNR1AMTNR1BCNR1CNR2
SCHEMBL5439359 0.80 EPHX2 (0.45) CASRMTNR1AMTNR1BCNR1CNR2
SCHEMBL5440348 0.80 EPHX2 (0.45) CASRMTNR1AMTNR1BCNR1CNR2
SCHEMBL5435301 0.79 METAP2 (0.51) CASREPHX2LMNA
SCHEMBL5437644 0.79 METAP2 (0.51) CASREPHX2LMNA
SCHEMBL1426449 0.78 MTNR1A (0.56) CASRMTNR1AMTNR1BCNR1CNR2
SCHEMBL5297701 0.77 CYP3A4 (0.58) CASRMTNR1AMTNR1BEPHX2APAF1
SCHEMBL3510106 0.76 MTNR1A (0.53) CASRMTNR1AMTNR1BCNR1CNR2
SCHEMBL2726416 0.76 MTNR1A (0.72) CASRMTNR1AMTNR1BCNR1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7727997-B2 N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives ELAN PHARMACEUTICALS, INC. (US) 2010-06-01 US disclosed
US-20070213316-A1 Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease ELAN PHARMACEUTICALS, INC. 2007-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213316-A1 Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease BACE1, BACE2, APP CASR 2012/4885MTNR1A 1047/4885MTNR1B 778/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.